CoChat

Inflammation and Atherosclerosis: The End of a Controversy

Hansson, Göran K. · 2017 · Circulation
Cited by 149

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

oes inflammation matter in coronary artery disease?Is it a driving force in atherosclerosis or merely an epiphenomenon?Is there space for novel therapies besides those targeting cholesterol?The CANTOS trial (Canakinumab Anti-inflammatory Thrombosis Outcomes Study), which was presented at the European Society of Cardiology meeting in Barcelona a few weeks ago, provides answers to these important questions.Indeed, the results of this trial open up a new avenue for cardiovascular prevention.Atherosclerosis, the underlying pathology in most cases of myocardial infarction, ischemic stroke, and ischemic gangrene, is a disease of complex genesis that has remained controversial for decades.Clinical and experimental studies have provided unequivocal evidence for an etiologic role of cholesterol and also offered strong support for a pathogenic role of inflammation. 1 By targeting cholesterol, blood pressure, and cigarette smoking, cardiovascular prevention has become one of the great success stories in medicine.We have witnessed a reduction in the incidence of myocardial infarction by ≈40% in large parts of the world during the past 2 decades, and a substantial part of this decrease can be ascribed to preventive medicine. 1Cholesterol-lowering statin therapy reduces the incidence of major adverse cardiovascular events by 25% to 50% in individuals with elevated low-density lipoprotein cholesterol and has become standard therapy for a large segment of the population in the Western world.The success of statins made us wonder whether we could realistically expect any further improvement in cardiovascular prevention.This attitude gained further support when it was found that statins also have anti-inflammatory properties.Although residual risk after myocardial infarction remains high, many clinicians and investigators did not see any reason for further development of cardiovascular prevention.The results of the CANTOS study demand a reassessment of the situation. 2ANTOS is a randomized, double-blind secondary prevention trial in 10 061 patients with prior myocardial infarction and elevated levels of the inflammation marker, high-sensitive C-reactive protein (>2 mg/L). 2 In all, 80% of the study participants were treated for hypertension, 40% had diabetes mellitus, and >90% were on statin therapy.They were randomized into 4 groups that received canakinumab, a human monoclonal antibody to the inflammatory cytokine, interleukin (IL)-1β at 3 different dosages, or placebo.Canakinumab is currently used clinically in some rare autoinflammatory conditions and as a second line of treatment in rheumatoid diseases.As expected, canakinumab reduced high-sensitive C-reactive protein levels; it had no substantial effect on plasma lipids. 2 The primary end point of the study was the first occurrence of myocardial infarction, stroke, or cardiovascular death.Canakinumab reduced this end point significantly, from 4.5 per 100 person-years in the placebo group to 3.9 in the groups receiving ≥150 mg antibody per dose. 2 This translated to a 15% relative reduction Inflammation and AtherosclerosisThe End of a Controversy

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.117.030484

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 149

Metadata

Authors
Hansson, G. K.
Venue
Circulation
Published
2017-11-14
Volume
136
Issue
20
Pages
1875-1877
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2754580435
Cited by
149
References
4
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.